Advertisement

IN BRIEF / BIOTECHNOLOGY

Biogen Wins OK for Psoriasis Drug

February 01, 2003|From Times Wire Services

Biogen Inc. won U.S. approval to sell a treatment for psoriasis that lacks side effects of older drugs and could bring it $500 million in annual sales.

Amevive, an injected medicine, won Food and Drug Administration clearance for patients with a form of the skin disease called moderate-to-severe chronic plaque psoriasis.

The drug is expected to face competition from Amgen Inc.'s arthritis drug Enbrel, which is being studied as a psoriasis treatment.

Advertisement
Los Angeles Times Articles
|
|
|